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Introduction: A phosphorylation score for estrogen receptor-alpha (ERα), called P7 score, was shown previously to
be an independent prognostic factor in breast cancer patients treated with tamoxifen. Since mechanistic target of
rapamycin (mTOR) activation is implicated in resistance to endocrine therapy in breast cancer we determined
whether mechanistic target of rapamycin complex 1 (mTORC1) activation, measured by phosphorylation on S2448
(p-mTOR), was associated with the P7-score and/or clinical outcome in the same cohort.
Methods: mTOR phosphorylation status was determined at S2448 residue in vivo by immunohistochemistry in a
cohort of more than 400 well-characterized ERα positive breast tumors. MCF7 cells were treated with estrogen and
activation of mTOR pathway was determined by Western blotting.
Results: Contrary to earlier reports, p-mTOR expression, measured by immunohistochemistry, was negatively associated
with size and nodal status. Additionally, p-S2448 mTOR expression was positively correlated with p-S118- ERα,
p-S167-ERα and p-S282-ERα but negatively correlated with p-T311- ERα. Consistent with these, p-S2448 mTOR
was negatively associated with P7-score and was significantly associated with overall survival (OS) (hazard ratio
(HR) = 0.61, P = 0.028, 95% confidence interval (CI) 0.39 to 0.95, n = 337) and relapse-free survival (HR = 0.58, P = 0.0032,
95% CI 0.41 to 0.83, n = 337) following univariate but not multivariate analysis. Furthermore, we show that estrogen can
regulate phosphorylation of mTOR and its down stream target p70S6 kinase. Additionally, recombinant mTOR can
phosphorylate ERα in vitro.
Conclusions: These data suggest that in breast tumors where there is intact estrogen regulated signaling, mTOR is
regulated by estrogen and therefore associated with an increased likelihood of responsiveness to endocrine therapy.Introduction
The estrogen receptor-α (ERα) status of breast tumors is
the gold-standard marker for predicting response to endo-
crine therapy. This is due primarily to its central role in
estrogen signaling within ERα + breast cancer [1]. How-
ever, ERα status as currently measured does not accurately
predict treatment response since at least 50% of ERα +
tumors are de novo resistant to endocrine therapies* Correspondence: Leigh.Murphy@med.umanitoba.ca
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unless otherwise stated.such as tamoxifen, and many of those initially sensitive
will acquire resistance despite the continued expression
of non-mutated ERα in most cases [2]. ERα, like many
other proteins, can be post-translationally modified [3].
Post-translational modifications (PTMs), such as phos-
phorylation, acetylation, methylation and ubiquitination
of ERα, have been identified and, in some cases, shown
to affect ERα activity [3]. Investigation of the relevance
of phosphorylated forms of ERα in vivo in human breast
tumors revealed that many breast tumor biopsy samples
have detectable phosphorylated ERα [4,5]. Recently, we
determined expression of seven different phosphorylated
residues on ERα in breast cancer samples from patients
who subsequently were treated with tamoxifen, and found
that multiple tumors expressed combinations of phospho-ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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some of these phosphorylated sites was significantly asso-
ciated with good and others with poor clinical outcome
[6,7]. This led us to define an ERα phosphorylation score
which takes into account the presence of all seven phos-
phorylated ERα epitopes detected in any one tumor. This
so-called P7-score was found to be significantly associated
with overall survival from breast cancer death and relapse
free survival (RFS) in multivariate analysis [6]. Such data
support the hypothesis that a phosphorylation code for
ERα exists that is a more accurate prognostic and, pos-
sibly, treatment response marker than determination of
the expression of ERα alone. It also suggests that ERα
is a central node at which integration of diverse signals
occurs to regulate breast cancer growth and survival.
We have hypothesized that the P7-score represents the
balance of estrogen-dependent (ligand-dependent) and
ligand-independent ERα signaling associated with any
tumor [6]. These data highlight the potential role
played by kinases in breast tumors in vivo [8-10] re-
sponsible for maintaining the ERα phosphorylation
code, as they may provide targets for development of
new ‘endocrine’ or alternative therapies.
It has been suggested that increased activation of the
mechanistic target of rapamycin (mTOR) pathway [11],
possibly through the PI3K/Akt pathways, plays a role in
endocrine resistance exhibited by some ERα + breast can-
cer cells, since inhibition of mTOR signaling with rapamy-
cin could restore sensitivity to tamoxifen in laboratory
models of resistance [12,13]. Furthermore, p70-S6kinase
(p70S6K), a downstream target of activated mTOR, was
shown to directly phosphorylate ERα on Ser167 and in-
crease the transcriptional activity of ERα [14]. The possi-
bility exists that increased activated mTOR may help drive
ligand-independent ERα signaling and short circuit the
ligand-dependent pathway that is most sensitive to inhib-
ition by endocrine therapies. In this study, we have evalu-
ated the relationship between activated mTOR signaling
and the ERα phosphorylation score, as a measure of the
balance of ligand-dependent and -independent ERα sig-
naling, using human breast cancer cases, where the pa-
tient subsequently received adjuvant tamoxifen therapy.
Methods
Materials/reagents
Recombinant human ER (rh-ERα) was from Invitrogen
(Carlsbad, CA, USA), recombinant human mTOR (rh-
mTOR, catalytic subunit) was from BPS Bioscience (San
Diego, CA, USA) and recombinant human p70S6 kinase
(rh-p70S6K) was from R&D Systems, Inc (Minneapolis, MN,
USA). AZD8055, a selective, ATP-competitive mTOR kinase
inhibitor was from Cedarlane (Burlington, ON, Canada). PF-
4708671, a selective p70-S6kinase inhibitor, was from EMD
Millipore Co. (Cedarlane, Burlington, ON, Canada).Tissue microarrays
All primary invasive breast cancers used in this study
were from the Manitoba Breast Tumor Bank (MBTB,
CancerCare Manitoba and University of Manitoba)
[15,16]. MBTB embraces the policies and operating pro-
tocols of the Canadian Tumor Repository Network [17]
and operates with approval from the Research Ethics
Board of the Faculty of Medicine, University of Manitoba.
The histopathology of MBTB biospecimens was previ-
ously assessed and entered into a computerized database
to enable selection based on tissue composition and
clinical-pathological parameters. Tissue collection and
sample selection for tissue microarray (TMA) con-
struction was reported before [6]. ERα positive status
was determined by ligand binding assay (>3 fmol/mg
protein) at the time of diagnosis and confirmed by im-
munohistochemistry (IHC) in the TMAs as previously
described [5]. Although 450 cases were represented on
the original TMAs, due to exhaustion of some tumor cores
from previous use of the TMAs, the tumor numbers (n)
analyzed for some markers were less than 450. The study
cohort characteristics have been previously published [6]
and did not change significantly due to exhausted tumor
core drop out: the current cohort characteristics are pro-
gesterone receptor (PR)-positive (>20 fmol/mg protein),
62.5% (261/336); PR-negative, 37.5% (126/336); low-grade,
27.7% (93/336); intermediate-grade, 61.6% (207/336); high-
grade,10.7% (36/336); tumor size <2.5 cm, 55.5% (187/337);
tumor size ≥2.5 cm, 44.5% (150/337); age <50 years, 6.9%
(23/335); age >50 years, 93.1% (312/335); node-negative,
49.6% (164/331); node-positive, 50.5% (167/331). The me-
dian follow-up was 99 months (range 9 to 217 months).
Antibodies
The P7-scores for the study cohort were previously deter-
mined and reported [6]. The antibodies used for IHC were
validated as previously described [5]: mTOR (rabbit
monoclonal, 7C10) and mTOR phosphorylated on serine
2448 (p-S2448 mTOR; rabbit monoclonal, 49 F9), anti-
bodies and blocking peptides were from Cell Signaling
Technology Inc. (NEB Ltd, Whitby, ON, Canada).
p70S6kinase (p70S6K, N-terminal; rabbit monoclonal,
clone E343, cat # 1494–1), p70S6K phosphorylated on
threonine 389 (p-T389 p70S6K; rabbit monoclonal, clone
E175, cat # 1175–1, or Cell Signalling, rabbit monoclonal
108D2, cat#9234) and blocking peptides were from Epi-
tomics Inc (Burlingame, CA, USA). Validation of p-2448
mTOR and p-T389p70S6K is shown in Additional file 1:
Figure S1. Similar validations were undertaken for p70S6K
and mTOR (not shown). The anti-phosphoserine anti-
body (ab9332) was from Abcam Inc (Cambridge, MA,
USA). The antibodies used for immunoprecipitation/West-
ern blotting were against total mTOR/FKBP12-rapamycin
complex-associated protein (FRAP) (sc-1549-R) and total
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Cruz, CA, USA). Although in Additional file 1: Figure
S1 there appears to be a partial reduction in IHC signal
due to the non-phosphorylated peptide (+mTOR) and
an irrelevant p-peptide (+pS118), close examination of
Additional file 1: Figure S1C and 1D and comparison to
Additional file 1: Figure S1A shows that the dynamic
signal intensity range among positive cells is similar. In
Additional file 1: Figure S1D there is a very dark brown
staining section (going clockwise from the top of the
circle) between 180° and 270° as well as a small circle
of intense staining at approximately 180°; in Additional
file 1: Figure S1C an intensely staining focus of cells is
found at approximately 90° and 135°. These are similar
in intensity to regions in Additional file 1: Figure S1A.
Even in Additional file 1: Figure S1A there is a range of
staining intensities reflecting the heterogeneous nature of
tumors and the cells within them. Each different staining
is done on a serial section which increases the heterogen-
eity. It should be noted, as well, that the counter-stain in
Additional file 1: Figure S1A is generally more intense
than Additional file 1: Figure S1C and 1D, which affects
the perception of intensity. In contrast, all signal is lost in
Additional file 1: Figure S1B where the antibody is pre-
absorbed with excess of the specific phospho-peptide. The
data seen in these figures support the well-known hetero-
geneity of expression of any protein that seems to occur
in breast tumor cells in vivo in a breast biopsy specimen.
So perceived differences, we argue, are due primarily to
tissue composition and tumor cell heterogeneity and not
due to a lack of phospho-epitope specificity, although we
cannot completely eliminate this possibility.
Tissue collection times
As previously described [5], a cohort of breast tumors
for which the collection time has been defined previ-
ously [5], is available in the Manitoba Tumor Bank. This
timed collection cohort was used to determine if detec-
tion of p-mTOR and p-p70S6K varied significantly with
time of biospecimen collection. Formalin fixed-paraffin em-
bedded blocks from 133 cases had sufficient material to be
used for this study. IHC for both p-mTOR and p-p70S6K
was carried out on adjacent sections. Within this cohort
the collection time ranged from 5 to 276 minutes
(mean 56 minutes and median 45 minutes). Although
there may be a trend for the p-mTOR IHC score to de-
crease with time no statistically significant relationship be-
tween collection time and p-mTOR (spearman r = −0.16,
P = 0.066, n = 133) or p-p70S6K (spearman r = 0.064,
P = 0.47, n =130) was found. The tumors were also divided
into groups based on collection times of ≤30 minutes
versus >30 minutes. Mann–Whitney two tailed analyses
showed no significant differences in the IHC score be-
tween the two time groups for either p-mTOR (P = 0.064)or p-p70S6K (P = 0.81) as illustrated in Additional file 2:
Figure S2.
Immunohistochemistry
IHC for TMAs was performed as described previously
[18]. Serial sections (approximately 5 μm) were stained
with antibodies as previously described [5]. Briefly, sec-
tions were submitted to antigen retrieval (CC1, Ventana
Medical Systems, Tucson, AZ, USA) using an auto-
immunostainer (Discovery Staining Module, Ventana
Medical Systems), followed by one-hour incubation with
primary antibody and 32-minute incubation with sec-
ondary antibody. Primary antibody concentrations ini-
tially applied to the Ventana instrument were 1:50 for
antibodies to p-S2448 mTOR, mTOR, p70S6K and p-
T389 p70S6K translating into final concentrations of
1:150 after 1:3 dilution with buffer dispensed onto the
slide with the primary antibody.
Quantification and cut-off selection
Slides were scored using standard light microscopy. IHC
scores were derived from assessment of both average
staining intensity across the two tumor cores (scale 0 to 3)
and percentage of positive cells (0 to 100%). These two
scores, when multiplied, generate an IHC or H-score of 0
to 300. Cytoplasmic staining for mTOR and p-S2448
mTOR was scored. Little nuclear staining of mTOR or
p-S2448 mTOR was seen in this study cohort. Cyto-
plasmic and nuclear staining for p70S6K and p-T389
p70S6K were scored. TMAs were evaluated independ-
ently by two investigators (AS, CP). Where discordance
was found, cases were re-evaluated to reach consensus.
Since no relevant clinical cut-off points are presently re-
ported for mTOR, p-S2448 mTOR, p70S6K and p-T389
p70S6K, positivity reported in this study was empirically
based on IHC scores greater than the 50th percentile. RFS
was defined as time to first recurrence or death due to
breast cancer (censors were other death) and overall sur-
vival (OS) was defined as time to death due to breast can-
cer (censors were other death).
Cell culture and immunoprecipitation
MCF7, ER + human breast cancer cells were routinely
cultured in (D)MEM containing 5% (v/v) fetal bovine
serum (FBS), 1% (w/v) glucose, glutamine and penicillin–
streptomycin (5% complete medium (CM)). For experi-
ments, cells were estrogen depleted and serum starved for
four days in serum free-phenol red-free (D)MEM before
treatment with estradiol-17β (10 nM) or vehicle control
(ethanol) for various times. Cells were harvested at the
various time points and subjected to SDS polyacrylamide
electrophoresis (SDS-PAGE) and Western blotting as pre-
viously described [19]. For immunoprecipitation, cells were
grown as described above, washed twice with cold PBS and
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(DSP) for two hours at 4°C. The cross-linking was
quenched with 20 mM Tris–HCl for five minutes at
room temperature. Following that, cells were lysed by
sonication in lysis buffer (10 mM Hepes pH 7.5, 10%
glycerol, 150 mM NaCl, 1% NP40, 0.5% sodium deoxy-
cholate, 0.1% SDS) supplemented with complete protease
inhibitor cocktail (Roche, Mississauga, ON, Canada), 1
mM phenyl methyl sulfonyl fluoride (PMSF), 1 mM
Na3VO4, and 5 mM NaF. Lysates were incubated with
antibody overnight on a rotator at 4°C. Antibody-bound
protein complexes were precipitated from lysates using
Dynabeads Protein G (Life Technologies, Burlington,
ON, Canada). Dynabeads were washed six times with
wash buffer (10 mM Hepes pH 7.5, 10% glycerol, 150
mM NaCl, 1% NP40), followed by addition of sample
buffer (50 mM Tris–HCl pH6.8, 2% SDS, 6% glycerol,
0.1 M dithiothreitol (DTT)). Protein complexes were
resolved by SDS-PAGE and Western blotting, as above.
In vitro kinase assays
Recombinant proteins (300 ng rh-ERα, 100 ng rh-mTOR,
100 ng rh-p70S6K) were incubated alone or together in
kinase buffer (5X kinase buffer is 25 mM MOPS, 12.5
mM β-glycerophosphate, 25 mM MgCl2, 5 mM EGTA, 2
mM EDTA, 0.25 mM DTT) with or without, a final con-
centration of 2 mM ATP, usually in a final volume of 25
μl. Incubation was for 30 minutes at 30°C; reactions were
stopped by freezing. For inhibition assays, rh-ERα was
pre-incubated with 100 nM AZD8055, 10 μM PF-4708671
or vehicle control (DMSO) for 15 minutes at 30°C, prior
to the addition of ATP. Thereafter, reaction mixtures were
thawed and subjected to SDS-PAGE electrophoresis and
Western blot analysis.
Statistical methodology
Survival analysis used Cox regression analyses to examine
hazard ratios (HR). Each model was tested and all com-
plied with the assumption of proportional hazard. These
statistical analyses were performed using SAS™version 9.2.
The probabilities shown in the single predictor models are
not corrected for multiple comparisons. The probabilities
in the multiple predictor model take into account the
presence of the other predictors, that is, tumor size, nodal
status, grade, PR expression, P7-score and p-mTOR.
Results
mTOR and pS2448-mTOR expression in human breast tumors
Previously constructed TMAs containing multiple sam-
ples of ERα + breast tumors were interrogated. IHC stain-
ing for both p-S2448 mTOR and total mTOR was
observed and was primarily cytoplasmic; however, nuclear
staining of both occurred in a minority of tumors
(approximately10%).Unexpectedly, it was found that total mTOR expres-
sion was negatively correlated with size and nodal sta-
tus (Spearman correlation r = −0.206, P = 0.0002, n = 329;
r = −0.27, P <0.0001, n = 323, respectively). Furthermore,
p-S2448 mTOR was also found to be negatively associated
with size and nodal status (r = −0.122, P = 0.026, n = 337;
r = −0.15, P = 0.0068, n = 331, respectively). When tumors
were divided into node negative and positive categories
the median IHC scores for mTOR were significantly
different (median IHC score 225 versus 180 respect-
ively, P < 0.0001, Mann–Whitney two tailed, Additional
file 3: Figure S3). Similarly, p-S2448 mTOR IHC scores
were significantly different between node negative and
positive tumors (median IHC score 90 and 70, P = 0.0073,
respectively, Mann–Whitney two tailed, Additional file 3:
Figure S3). When tumors were dichotomized into small
(<2 cm) and large (≥2 cm) size, the median H scores for
mTOR were significantly higher in small versus large
tumor size (median H score 225 versus 180, respectively,
Mann–Whitney two tailed P = 0.012, Additional file 4:
Figure S4). In contrast, the same analysis for p-S2448
mTOR showed no significant difference (Additional file 4:
Figure S4). Together these data suggested the possibility
that an activated mTOR pathway, possibly associated with
mTORC1, is a good prognostic factor in primary human
ERα + breast cancer.
Association of mTOR/p-S2448 mTOR with clinical
outcome in patients treated with tamoxifen
The cohort of breast cancer cases interrogated for
mTOR and p-S2448 mTOR represented primary ERα +
tumors from patients who received adjuvant tamoxifen
therapy after surgery. Therefore, the relationship of
mTOR and p-S2448 mTOR to clinical outcome defined
by RFS (RFS = endpoint recurrence and/or death due to
BC, Table 1) and OS from death due to breast cancer
(OS = endpoint death due to breast cancer, Table 2) was
determined. Expression of mTOR was not significantly
associated with clinical outcome, as shown in Table 1
and Figure 1A and B. However, high levels of p-S2448
mTOR (defined by >median H score 80) were found to
be significantly associated with better clinical outcome,
both OS (Table 2, HR = 0.61, P = 0.028, 95% CI 0.39 to
0.95, n = 337) and RFS (Table 1, HR = 0.58, P = 0.0032,
95% CI 0.41 to 0.83, n = 337) as shown in Figure 1C and
D. However, this did not remain significant on multivari-
ate analysis.
Association of mTOR/p-S2448 mTOR with the P7-
phosphorylation score for ERα
Previously, we had determined expression of seven dif-
ferent phosphorylated residues on ERα in these same
breast cancer samples from patients who subsequently
received adjuvant tamoxifen therapy, and found that
Table 1 Multivariate analysis of factors associated with recurrence free survival (RFS)
Single predictor Number Hazard ratio 95% CI on HR P
Age 50+ versus <50 420 1.57 0.80 to 3.07 0.19
Tumor >2.5 cm 422 1.85 1.36 to 2.51 <.0001
Node Pos versus Neg 415 2.02 1.48 to 2.76 <.0001
Grade (Low, Mid High) 420 1.45 1.12 to 1.88 0.0055
PR_LBA >20 421 0.6 0.44 to 0.81 0.0010
P7 Score High 340 2.23 1.37 to 3.61 0.0012
pmTor >80 337 0.58 0.41 to 0.83 0.0032
mTor >180 329 0.73 0.51 to 1.04 0.084
Multi predictor
Age 50+ versus <50 277 1.34 0.53 to 3.36 0.54
Tumor >2.5 cm 1.77 1.20 to 2.61 0.0041
Node Pos versus Neg 1.61 1.07 to 2.43 0.022
Grade (Low, Mid High) 1.21 0.88 to 1.64 0.24
PR_LBA >20 0.61 0.42 to 0.89 0.011
P7 Score High 1.77 0.99 to 3.18 0.054
pmTor >80 0.80 0.54 to 1.20 0.28
CI, confidence interval; mTOR, mechanistic target of rapamycin; PR_LBA, Progesterone Receptor Ligand Binding Assay.
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lated ERα epitopes [5,6]. We also established that some
phosphorylation sites were significantly associated with
good and others with poor clinical outcome. From this,
we defined an ERα phosphorylation score, taking into
account the phosphorylation status of ERα at each of the
seven sites interrogated. This so-called P7-score wasTable 2 Multivariate analysis of factors associated with
overall survival from death due to breast cancer (OS)
Single predictor Number Hazard ratio 95% CI P
Age 50+ versus <50 420 1.67 0.74 to 3.81 0.22
Tumor >2.5 cm 422 2.27 1.56 to 3.30 <.0001
Node Pos versus Neg 415 2.06 1.42 to 3.00 0.0002
Grade (Low, Mid High) 420 1.38 1.02 to 1.87 0.035
PR_LBA >20 421 0.61 0.42 to 0.87 0.0068
P7 Score High 340 2.78 1.45 to 5.35 0.0022
pmTor >80 337 0.61 0.39 to 0.95 0.028
mTor >180 329 0.87 0.56 to 1.35 0.53
Multi predictor/Selection model
Age 50+ versus <50 277 0.93 0.33 to 2.68 0.90
Tumor >2.5 cm 1.98 1.23 to 3.21 0.0053
Node Pos versus Neg 1.92 1.14 to 3.26 0.015
Grade (Low, Mid High) 1.21 0.83 to 1.76 0.32
PR_LBA >20 0.70 0.44 to 1.11 0.12
P7 Score High 2.57 1.09 to 6.06 0.032
pmTor >80 0.95 0.58 to 1.55 0.84
CI, confidence interval; mTOR, mechanistic target of
rapamycin; PR_LBA, Progesterone Receptor Ligand Binding Assay.significantly associated with OS from breast cancer
death and RFS in multivariate analysis [6]. Due to the
relationship of p-S2448 mTOR with clinical outcome in
this cohort, we investigated the relationship of p-S2448
mTOR to different phosphorylated forms of ERα in
these samples. p-S2448-mTOR was positively correlated
with p-S118-ERα (r = 0.268, n = 308, P <0.0001), p-S167-
ERα (r = 0.205, n = 325, P = 0.0002) and p-S282-ERα
(r = 0.188, n = 304, P = 0.001), but negatively corre-
lated with p-T311-ERα (r = −0.125, n = 307, P = 0.028).
Previously [6] we had shown that detection of several
phosphorylation sites on ERα, p-S104/106-ERα, p-S118-
ERα, p-S167-ERα, p-S282-ERα and p-S294-ERα, was asso-
ciated with a good clinical outcome while p-T311-ERα
and p-S559-ERα were associated with poor clinical out-
come. In the current study we found that p-mTOR was
positively associated with p-S118-ERα, p-S167-ERα and
p-S282-ERα but negatively associated with p-T311-ERα,
which suggested an inverse relationship with the P7-
ERα score and, indeed, p-S2448 mTOR expression was
found to be negatively correlated with P7-ERα score
(r = −0.23, n = 284, P <0.0001). When tumors were di-
chotomized into high P7-ERα score (defined by the
clinically relevant ≥3 cut-off described previously) ver-
sus low P7-ERα score (<3) the IHC scores for p-S2448-
mTOR were significantly higher in low versus high P7-ERα
score tumors (median IHC score 90 versus 70, respectively,
Mann–Whitney two-tailed P = 0.0005, Figure 2). These
data further support an association of high p-S2448-
mTOR with good prognosis. Since the P7-score remained
significant on multivariate analysis as previously described
Figure 1 Kaplan-Meier estimates of relapse free survival from breast cancer recurrence (A, C) or breast cancer specific death (B, D)
with respect to expression of total mTOR (A, B) and p-mTOR (C, D). P value represents the significance of a simple survival analysis without
the proportional hazard assumption that was applied in the analyses presented in Tables 1 and 2. mTOR, mechanistic target of rapamycin.
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lationship of p-S2448-mTOR to the P7-score is likely
driving its association with clinical outcome.
Nuclear staining for p-S2448-mTOR has been previ-
ously reported [20] and in the current cohort was de-
tected in approximately 10% (38/352) of assessable
cases. Nuclear p-S2448-mTOR was correlated with cyto-
plasmic p-mTOR (r = 0.495, n = 38, P = 0.0018) and
while nuclear p-S2448-mTOR showed similar trends in
terms of relationships to phosphorylated P7 ERα score,
it was not analyzed further due to the small numbers of
positive cases.
Relationship of p70S6K to activated mTOR and
phosphorylated ERα
To explore further the relationship of phosphorylated
ERα to the activated mTOR pathway, specifically the
mTOR complex 1 (mTORC1), TMA sections from the
above breast cancer cohort were examined for the ex-
pression of p70S6K, a downstream target of p-S2448-mTOR within the mTORC1 [21]. Both nuclear and cyto-
plasmic staining for p-T389-p70S6K and total p70S6K
has been reported and both were scored separately in
the above cohort [22]. The majority of cases were posi-
tive for both cytoplasmic and nuclear p-T389-p70S6K as
well as total p70S6K. As expected both cytoplasmic and
nuclear p-T389-p70S6K and total p70S6K were posi-
tively correlated with both total and p-S2448-mTOR.
Neither cytoplasmic nor nuclear p-T389-p70S6K was as-
sociated with the P7-ERα score. However, total nuclear
p70S6K showed a weak inverse correlation with the P7-
ERα score (r = − 0.183, n = 273, P = 0.0024). When tumors
were dichotomized into high P7-ERα score (defined by
the clinically relevant ≥3 cut-off described previously, [6])
versus low P7-ERα score (<3) the median IHC scores for
total nuclear p70S6K were significantly higher in low
versus high P7-ERα score tumors (median IHC score 62
versus 20, respectively, Mann–Whitney two tailed P= 0.034,
Additional file 5: Figure S5). Positive correlations of
total nuclear p70S6K expression with p-S104/106-ERα
Figure 2 p-S2448-mTOR expression as determined by
immunohistochemistry is inversely related to P7-score in ER +
primary breast cancer. Tumors were dichotomized into high P7-score
(>3) and low P7-score (<3). The histograms show mean ± SEM for the
two groups. The median H -scores were significantly different between
the two groups for p-S2448-mTOR but not total mTOR using a
Mann–Whitney two tailed statistical analysis. ER, estrogen receptor;
mTOR, mechanistic target of rapamycin; p-S2448-mTOR, mTOR
phosphorylated on serine 2448; SEM, standard error of the mean.
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n = 298, P= 0.0025), p-S167-ERα (r = 0.12, n = 315, P= 0.03)
and p-S282-ERα (r = 0.128, n = 302, P = 0.026) were
found. When tumors were dichotomized into high (de-
fined by the median IHC ≥20) versus low total nuclear
p70S6K expression, the median IHC for p-S104/106-
ERα, p-S118-ERα, p-S167-ERα and p-S282-ERα were
significantly higher in the high versus the low total nuclear
p70S6K groups (Mann–Whitney two-tailed P = 0.0079;
P = 0.0135; P = 0.02; P = 0.04, respectively). However, no
associations of p70S6K (phosphorylated or total) with
clinical outcome were found.Estrogen induces activation of mTOR and its downstream
target p70S6K
Several studies have indicated that estrogen can induce
activation of the mTOR pathway in estrogen target tis-
sues including breast cancer cells [23-26]. Activation of
the mTOR pathway was usually established by demon-
strating activation or inhibition of up- or down-stream
targets of mTOR [13,27]. However, the ability of estrogen
to regulate phosphorylation of mTOR in breast cancer
cells has not been reported. The observed correlation be-
tween a direct marker of mTOR activation, p-S2448
mTOR, and the P7-ERα score in ERα + primary breast
cancer cases prompted us to investigate the ability of es-
trogen to regulate phosphorylation of mTOR in MCF7
human breast cancer cells. MCF7 cells were depleted ofestrogen and serum starved overnight prior to treatment
with estrogen for various times. As shown in Figure 3,
estradiol (E2) treatment for three to six hours was asso-
ciated with a small (mean ± SD; at three hours 1.5 ± 0.2
fold, n = 7; at six hours 1.4 ± 0.3 fold, n = 5; one way
analysis of variance (ANOVA) P = 0.0006) but consist-
ent induction of p-S2448 mTOR. Furthermore, E2
treatment for three and six hours also resulted in the
phosphorylation of p70S6K at threonine 389 (Figure 3)
(mean ± SD; for three hours 1.9 ± 0.5 fold n = 10; at six
hours 1.6 ± 0.3 fold, n = 10, one way ANOVA P <0.0001).
These latter results are in agreement with previous reports
[27]. These data provide support for the ability of estrogen
to affect activation of mTOR and one of its downstream
targets in MCF7 human breast cancer cells.
Previously, we found that several serine residues in
ERα resided within motifs that suggested their potential
to be FRAP/mTOR substrates [28]. Therefore, to deter-
mine the potential of mTOR to directly phosphorylate
ERα, an in vitro kinase assay was performed using full-
length recombinant human ERα (rh-ERα) incubated
with the catalytic domain of recombinant human mTOR
(rh-mTOR) or with full-length recombinant human-
p70S6K (rh-p70S6K), since it has previously been shown
to phosphorylate ERα. As expected, rh-p70S6K increased
the phosphorylation of rh-ERα at serine residues by six
fold (mean, range three to nine, n = 2) and importantly
rh-mTOR increased the phosphorylation of rh-ERα at
serine residues by 4.4 ± 1.7 fold (mean ± SD, n = 3)
(Figure 4A). Preincubation with a selective mTOR in-
hibitor, AZD 8055, inhibited the serine phosphoryl-
ation of rh-ERα in the presence of mTOR but not
p70S6K, and preincubation with a selective inhibitor to
p70S6K, PF-4708671, inhibited serine phosphorylation
of rh-ERα in the presence of p70S6K but not mTOR
(Figure 4A). As a positive control for the activity of rh-
mTOR, an aliquot was incubated with rh-p70S6K plus
or minus ATP and western blotted for p-T389-p70S6K
(Figure 4B). As expected, rh-mTOR increased the phos-
phorylation of T389-p70S6K. Another control, where rh-
ERα was incubated with rh-p70S6K with and without
ATP and western blotted for p-S167-ERα also showed the
expected increase in p-S167-ERα (Figure 4C). These data
establish at least the potential for mTOR to phosphorylate
ERα.
To determine if mTOR and ERα could interact in in-
tact cells, appropriately treated cells were cross-linked
using DSP and co-immunoprecipitation (co-IP) undertaken.
Figure 5 shows that ERα was co-immunoprecipitated with
antibodies specific for mTOR but not with irrelevant
antibodies, although little difference due to treatment
was detected. These data suggest that ERα can exist in
a complex with mTOR supporting a possible direct
interaction and regulation of the two proteins. Similar
Figure 3 Effect of estrogen treatment on p-S2448-mTOR and p-p70S6Kinase in MCF7 human breast cancer cells. MCF7 were serum starved
and estrogen depleted and then treated with and without E2 (10 nM) for the indicated time periods. Cell extracts were prepared and analyzed as
described in the Methods section: 100 ug of extr0061ct was subject to Western blotting for p-mTOR, total mTOR, p-p70S6K and total p70S6K. Results
represent one of four to seven independent experiments. Upper panel: for p-S2448-mTOR, E2 treatment for three hours showed a 1.5 ± 0.2 fold, n = 7
(mean ± SD) and at six hours 1.4 ± 0.3 fold, n = 5 (one way ANOVA P = 0.0006) increase. Middle panel: for p-T389-p70S6K, E2 treatment for three hours
showed a 1.9 ± 0.5 fold, n = 10 (mean ± SD) and at six hours 1.6 ± 0.3 fold, n = 10 (one way ANOVA P < 0.0001) increase. ANOVA, analysis of variance;
E2, estradiol; mTOR, mechanistic target of rapamycin; p-S2448 mTOR, mTOR phosphorylated on serine 2448; SD, standard deviation.
Figure 4 mTOR can phosphorylate ERα in vitro. A) 300 ng of rh-ERα alone (full-length human ERα), or in the presence of 100 ng of mTOR
(mTOR/Raptor/MLST8 complex, catalytic domain) or 100 ng of p70S6K was subjected to in vitro kinase assays in the presence of 0.2 mM ATP for
30 minutess at 30°C. Reactions were pre-incubated for 15 minutess with DMSO (vehicle control) or with selective kinase inhibitors (100 nM mTOR
inhibitor AZ8055 or 10 μM p70S6K inhibitor PF-4708671). Following incubation, an aliquot of the reaction mix was subjected to Western blotting
and visualized with an antibody specific for phospho-serine residues. B) 100 ng of recombinant human p70S6K was incubated with 100 ng of
rh-mTOR (catalytic domain) with and without ATP as described in the Methods section. At the end of the incubation an aliquot of each reaction
was subjected to Western blotting and visualized with an antibody specific for p-T389-p70S6K. C) 300 ng of rh-ERα and 100 ng of recombinant
full-length p70S6K were incubated together in the presence or absence of ATP as described in the Methods section. At the end of the incubation
an aliquot of each reaction was subjected to Western blotting and visualized with an antibody specific for pS167-ERα. M =molecular mass marker.
DMSO, dimethyl sulfoxide; E2, estradiol; mTOR, mechanistic target of rapamycin; rh, recombinant human.
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Figure 5 ERα is co-immunoprecipitated with mTOR from MCF7
cells. MCF7 cells were grown in 5% CM (lane 1) or MCF7 were serum
starved and estrogen depleted and then treated with (lane 3) and
without E2 (lane 2) for 60 minutess. Cells were harvested, crosslinked
with DSP and immunoprecipitated with an isotype-matched but
irrelevant antibody (IgG) or an antibody specific for mTOR (sc-1549-R).
Aliquots of immunoprecipitated complexes were subjected to Western
blot analysis with antibodies to ERα or mTOR, as shown. Levels of
ERα and mTOR in input lysates are shown in the two lower panels.
A representative experiment is shown from a total of three independent
experiments. CM, complete medium; DSP, dithiobis(succinimidyl-
propionate); E2, estradiol; ERα, estrogen receptor α; IgG, immunoglobulin G;
mTOR, mechanistic target of rapamycin,
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p-mTOR were used for co-IP (data not shown).
Discussion
Since the mTOR pathway is a target for inhibition in
cancer treatment, and some previous studies have re-
ported a positive association of high levels of pS2448-
mTOR with poor prognosis in breast cancer [21,29-32],
the relationship we have found between p-S2448 mTOR
and the P7-score reflecting good outcome in patients
subsequently treated with adjuvant tamoxifen therapy,
was unexpected. However, the breast cancer cohort ex-
amined in the current study is distinct from previously
published cohorts, as it consisted entirely of primary
ERα+, sporadic cases, which contained both node posi-
tive and negative cases, the majority of women were
postmenopausal and the patients all received adjuvant
tamoxifen treatment following surgery and radiation.
Also, due to the nature of the tumor collection at the
MBTB, the cases are biased to larger sized tumors
[15,16]. Previously reported studies included cohorts
which: were ERα negative with the majority being triple
negative breast cancers [21], contained both ERα + and
ERα- cases with the majority being defined as low risk
(small tumor size and node negative) [32], had noinformation available concerning therapies [30], con-
sisted of mainly familial breast cancer cases where few
are ERα + [29] or consisted of a cohort in which only
50% of tumors were ERα+, or more than 60% of the
women were under 50 years of age [31].
Our data show that high levels of p-S2448 mTOR ex-
pression are associated with good clinical outcome in
ERα + patients, subsequently treated with tamoxifen, in
univariate but not multivariate analysis. We also found
p-S2448 mTOR expression was inversely associated with
the P7-ERα score, which is a prognostic factor (that is,
significantly associated with outcome on multivariate
analysis) in tamoxifen treated patients. This suggests
that activation of mTOR in this tumor cohort is associ-
ated with an intact estrogen (ligand) dependent signaling
pathway [33]. It is well known that if growth and sur-
vival of a tumor depends on estrogen and, therefore, an
intact, functional estrogen-dependent signaling pathway,
then endocrine therapies such as tamoxifen and aroma-
tase inhibitors are most likely to be of benefit to the
breast cancer patient [34]. Since the mTOR pathway is a
central regulator of cell growth, metabolism and survival
[11], it makes sense that estrogen (through ERα) would
regulate the mTOR pathway in cells that are dependent
on estrogen for growth, metabolism and survival. On the
other hand, activation of mTOR by amplification of
growth factor receptor pathways would be expected to
short circuit estrogen dependent regulation and be asso-
ciated with resistance to endocrine therapy [35]. This is
supported by experimental models as well as clinical as-
sociations and, as such, provides the rationale for com-
bining endocrine therapies and mTOR inhibitors, such
as rapamycin [11].
Clinical data supporting regulation of the mTOR path-
way by an intact estrogen signaling pathway are derived
from a neoadjuvant trial of letrozole, an aromatase in-
hibitor, where decreased detection of p-S2448-mTOR
following letrozole treatment was associated with a sig-
nificantly longer disease-free survival [25]. This latter
study suggests that in some breast cancers estrogen is
regulating the activation of mTOR and removal of estro-
gen, through aromatase inhibition, decreased mTOR
activation (at least as measured by decreased p-S2448-
mTOR). Our current data are, therefore, consistent with
this latter study.
The phosphorylated form of mTOR, assessed in the
current study, p-S2448, is a measure of activated mTORC1
[21]. Therefore, activated mTORC1 was found inversely re-
lated to the phosphorylation code or P7-score of ERα in
this breast cancer cohort [6]. While a low P7-ERα score
represents more phosphorylation at ERα sites associated
with good prognosis (for example, S118, S167, S282)
and clinical outcome, a high P7-ERα score represents
more phosphorylation at ERα sites associated with poor
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tients subsequently treated with tamoxifen [6]. Therefore,
the inverse relationship of activated mTORC1 with P7-ERα
score is consistent with activated mTORC1 being associ-
ated with better clinical outcome. However, since the P7-
score accounts for most of the variation that can also be
ascribed to p-mTOR, and they are correlated, not surpris-
ingly, this contributes to a loss of significance of p-mTOR
when they appear together in a multi-predictor model.
An exciting possibility supported by our data, is that
kinases associated with the activated mTORC1, includ-
ing mTOR itself or kinases regulated by mTORC1, could
be involved in phosphorylation of the ERα. High predic-
tion scores were found using the Kinexus Phosphonet
kinase predictor [36] for Ser118 and Ser294 in ERα as
substrates for mTOR. P70S6K is a downstream target of
the mTORC1 pathway [37] and has been shown to
phosphorylate ERα on Ser167 in cells in culture [14].
However, we found no relationship of p-T389-p70S6K
expression with p-S167-ERα or P7-score in the current
cohort. A weak correlation between total nuclear
p70S6K and p-Ser167, as well as other phosphorylated
ERα sites associated with good prognosis was observed,
which translated into a weak inverse correlation with the
P7-score. In contrast to p-S2448-mTOR, no relationship
to clinical outcome was found for total or phosphory-
lated p70S6K, nuclear or cytoplasmic.
Previous reports have suggested that estrogen can
regulate the mTOR pathway. Activation of mTOR was
most often determined by demonstrating activation of
p70S6K, a downstream target of mTOR, although other
markers of mTOR activation have also been used
[23,24,27]. However, direct evidence of mTOR phos-
phorylation was missing. We show here for the first
time, as far as we know, that phosphorylation of mTOR
at serine 2448 can be induced by estrogen in a time
dependent manner in MCF7 breast cancer cells and
mTOR can be coimmunoprecipitated with ERα in these
cells. These are small but reproducible effects. A possible
reason for the small effect may be that MCF7 cells are
cells derived from a pleural effusion, that is, metastatic
breast cancer, and the cells are usually only estrogen re-
sponsive and not estrogen dependent for growth and
survival, in cell culture [38,39]. Therefore, they may not
be an exact model for estrogen dependent ER + primary
breast cancer in vivo, as also suggested by a recent publi-
cation [40]. We also demonstrate that mTOR is capable
of phosphorylating ERα in vitro further supporting a re-
lationship between ER activation and mTOR activity.
Our in vitro and in vivo data suggest that there may be
multiple ways in which the ER pathway crosstalks with
the mTOR pathway, with both feed forward and feed-
back interactions such that when the balance is per-
turbed resistance to endocrine therapies can develop.Such interactions and their regulation require further
investigation.
Preanalytical variables around tissue collection are
now recognized to be important and a source of vari-
ation, particularly associated with PTMs, such as phos-
phorylation. PTMs are dynamic and marked changes in
phosphorylated epitopes that can occur in samples due
to the type of surgery, the type of biopsy and fixation
time, and other factors that may result in erroneous con-
clusions [41-43]. Although we cannot completely ex-
clude effects due to such issues, there are a number of
reasons why we feel issues of tissue collection and differ-
ential fixation are unlikely to explain the results we have
obtained. Firstly, the MBTB is populated primarily with
samples that were left over from tissue collected for ER/
PR assays performed by ligand binding. While some
study samples were from lumpectomies and some are
from mastectomies during the era that the samples were
collected (1988 to 2000), tumors were mostly large and
palpable clinically and on gross dissection and handled
the same way (that is, rapidly assessed and sampled be-
cause of the priority given to fresh sampling to conduct
ligand binding assays as this was the provincial standard
at the time for all breast cancer cases. Therefore, our
MBTB samples were derived in all cases from a path-
ology resection specimen that at the time of surgery was
rapidly assessed by the pathologist and both mastecto-
mies and lumpectomies were dissected and sampled im-
mediately (mean time approximately 50 minutess) to
obtain a fresh tumor sample that was then frozen in the
pathology laboratory. The samples were then transferred
to the provincial laboratory and frozen fragments cut
from each on a chilled surface for the clinical ER/PR lig-
and binding assay. After the assay was completed and
reported, the remaining frozen samples were passed to
the MBTB where all samples are divided on a dry ice
chilled surface to create mirror image blocks of tissue
and both blocks are returned to the freezer. Then a
block (typically 3 mm × 5 mm × 10 mm size) of each
pair is removed and immersed in formalin and fixed for
a set period (24 hours) and then processed in consistent
batches [15,44,45]. Therefore, the variation in delay in
sampling and freezing of tissues initially is small and the
delay and variation in fixation is also minimal and all
blocks are small and fixed for a standard length of time.
Secondly, although Pinhel et al., [41] show that levels
of phospho-epitopes are consistently lower in specimens
where there was a delay in fixation, there is still a very
good correlation between cores and resection levels in
individual cases. Therefore, mixing cores and resection
specimens in a single study is likely to suffer from issues
of variability between types of specimens but still their
data suggest that the relative expression levels within
each type of specimen are maintained. Therefore, while
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cores this would mostly affect the linear range of detec-
tion rather than the overall rank order among cases. Our
study examines one type of biospecimen (resections)
and all were collected in a relatively standardized fash-
ion. Furthermore, our timed collection data suggest that
there was minimal loss of epitope in our cohort.
Thirdly, we show a relative and inverse correlation of
p-mTOR with overall P7-ERα score, which is a complex
relationship (negative and positive) of detection of sev-
eral different p-ERα sites some of which we have shown
are related to good and some to poor clinical outcome
[6]. Despite the possibility that different phospho-
epitopes are potentially differentially influenced by
fixation time, we have identified a biologically plausible
relationship. The hypothesis derived from this is also
consistent with some results in the literature (i.e. cor-
relative in neoadjuvant trials [25]; and those using
laboratory models both cell lines and target tissues from
animals [24,26,27]). Furthermore, when we show data
using laboratory models which have tested the hypoth-
esis with some success. This also suggests that issues of
fixation are less likely an issue.
Conclusions
In summary, in primary tumors from an ER + cohort of
breast cancer patients who were subsequently treated
with tamoxifen, increased activated mTORC1 was found
to be associated with better clinical outcome but was
not an independent prognostic factor. Since activated
mTORC1 was also inversely correlated with the phos-
phorylation score of ERα (P7-score), and the P7-score
has previously been shown to be a significant independ-
ent prognostic factor in this cohort, we conclude that ac-
tivated mTORC1 is due to an intact estrogen dependent
signaling pathway in this breast cancer cohort.
Additional files
Additional file 1: Figure S1. Immunohistochemical validation of P-S2448-
mTOR antibodies in biopsies of representative human invasive breast
cancers cores represented on TMAs. IHC was performed as described in
the Materials and Methods. Adjacent sections of cores from breast
cancer cases represented on a test TMA available in MBTB, where (A)
stained with the p-S2448-mTOR antibody alone showing cytoplasmic
staining; (B) an adjacent section of the cores using p-S2448-mTOR
antibody antibody pre-absorbed with excess of the p-S2448-mTOR
phosphorylated peptide; or (C) pre-absorbed with excess irrelevant
ERα peptide phosphorylated at S118; or (D) pre-absorbed with the
non-phosphorylated mTOR peptide; (E) stained with phospho-p70S6K
(p-p70S6K) antibody alone; (F) an adjacent section of the cores using
phospho-p70S6K antibody pre-absorbed with excess of the phosphorylated
p70S6K peptide used to raise the antibody. All magnifications x 100.
Additional file 2: Figure S2. Investigation of the expression of p-S2448-
mTOR and p-T389-p70S6K in breast tumors in vivo due to tissue collection
time. The timed collection cohort of tumors was also divided into groups
based on collection times of ≤30 minutess versus >30 minutess. Mann–Whitney two-tailed analyses showed no significant differences in the IHC
score for either phospho-epitope between the two time groups.
Additional file 3: Figure S3. mTOR and p-S2448-mTOR expression as
determined by immunohistochemistry is inversely related to nodal status
in ER + primary breast cancer. Tumors were divided into node negative
and positive categories and the histograms show the means ± SEM of
the two groups. The median IHC-scores for mTOR and p-mTOR were
significantly different between node positive and negative subgroups
using a Mann–Whitney two tailed analysis.
Additional file 4: Figure S4. mTOR expression as determined by
immunohistochemistry is inversely related to tumor size in ER + primary
breast cancer. Tumors were dichotomized into small (<2 cm) and large
(>2 cm) size. The histograms show mean ± SEM for the two groups. The
median H-scores for mTOR were significantly different between the two
groups for total mTOR but not p-S2448-mTOR using a Mann–Whitney
two tailed statistical analysis.
Additional file 5: Figure S5. Nuclear p70S6K expression as determined
by immunohistochemistry is inversely related to P7 score in ER + primary.
Tumors were dichotomized into high P7 score (>3) and low P7 score
(<3). The histograms show mean ± SEM for the two groups. The median
H-scores were significantly different between the two groups for total
nuclear p70S6K expression using a Mann–Whitney two tailed statistical
analysis.
Abbreviations
Akt: serine-threonine protein kinase encoded by the v-akt murine thymoma
viral oncogene homolog gene; CM: complete medium; (D)MEM: (Dulbecco’s)
modified eagles medium; E2: estradiol; ERα: estrogen receptor-alpha;
FBS: fetal bovine serum; FRAP: FKBP12-rapamycin complex-associated
protein; HR: hazard ratio; IHC: immunohistochemistry; IP: immunoprecipitation;
MBTB: Manitoba Breast Tumor Bank; mTOR: mechanistic target of rapamycin;
mTORC1: mechanistic target of rapamycin complex 1; OS: overall survival;
p70S6K: p70 S6 kinase; P7-score: a measure of the presence of up to seven
phosphorylated ERα epitopes by immunohistochemistry in breast cancer
biopsy samples; PI3K: phosphatidylinositol-4,5-bisphosphate 3-kinase;
PBS: phosphate-buffered saline; PR: progesterone receptor; p-S2448
mTOR: mTOR phosphorylated on serine 2448; p-T389 p70S6K: p70S6K
phosphorylated on threonine 389; PTM: post-translational modifications;
RFS: relapse free survival; TMA: tissue microarrays.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AS contributed to the project design, conception, acquisition of data, analysis
and interpretation of data, drafting and revising the manuscript; MCB contributed
to acquisition of data, analysis and interpretation of data, drafting and revising
the manuscript; DJ, contributed to acquisition of new data, analysis of data and
revising the manuscript; TB, contributed to acquisition of data, analysis of data,
and revising the manuscript; SS, contributed to project design, acquisition of
data, analysis of data, and revising the manuscript; CP, contributed to acquisition
of data, analysis and interpretation of data, and revising the manuscript; ZN,
contributed to project design, analysis and interpretation of data, drafting and
revising the manuscript; PHW and LCM contributed to the project design,
conception, analysis and interpretation of data, drafting and revising the
manuscript and overall coordination and supervision of the study. All authors
participated in writing, editing and final approval of the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This work was supported by the Canadian Institutes of Health Research
(CIHR), the Canadian Breast Cancer Foundation (CBCF) and the Canadian
Cancer Society Research Institute (CCSRI). This study was also supported by
the Manitoba Breast Tumor Bank, a member of the Canadian Tumor
Repository Network and is funded in part by the CancerCare Manitoba
Foundation (CCMF) and CIHR. MCB is funded by a CBCF Postdoctoral
Fellowship. SS was funded by a postdoctoral fellowship from the Manitoba
Health Research Council (MHRC).
Shrivastav et al. Breast Cancer Research 2014, 16:R49 Page 12 of 13
http://breast-cancer-research.com/content/16/3/R49Author details
1Department of Biochemistry and Medical Genetics and the Manitoba
Institute of Cell Biology, University of Manitoba and CancerCare Manitoba,
675 McDermot Avenue, Winnipeg, MB R3E 0V9, Canada. 2Department of
Biology, University of Winnipeg, Winnipeg, MB, Canada. 3Manitoba Breast
Tumour Bank, Manitoba Institute of Cell Biology, University of Manitoba and
CancerCare Manitoba, Winnipeg, MB, Canada. 4Tumour Tissue Repository and
Deeley Research Center, BC Cancer Agency, Victoria, BC, Canada.
Received: 3 April 2013 Accepted: 2 May 2014
Published: 22 May 2014References
1. Ali S, Coombes R: Endocrine-responsive breast cancer and strategies for
combating resistance. Nature Rev 2002, 2:101–112.
2. Musgrove EA, Sutherland RL: Biological determinants of endocrine
resistance in breast cancer. Nat Rev Cancer 2009, 9:631–643.
3. Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L: Cracking
the estrogen receptor’s posttranslational code in breast tumors. Endocr
Rev 2011, 32:597–622.
4. Murphy LC, Seekallu SV, Watson PH: Clinical significance of estrogen
receptor phosphorylation. Endocr Relat Cancer 2011, 18:R1–R14.
5. Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Troup S, Begic S, Parisien M,
Watson PH, Murphy LC: Immunohistochemical validation of multiple
phospho-specific epitopes for estrogen receptor alpha (ERalpha) in
tissue microarrays of ERalpha positive human breast carcinomas. Breast
Cancer Res Treat 2009, 118:443–453.
6. Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, Murphy LC: A
phosphorylation code for oestrogen receptor-alpha predicts clinical
outcome to endocrine therapy in breast cancer. Endocr Relat Cancer 2010,
17:589–597.
7. Skliris GP, Nugent ZJ, Watson PH, Murphy LC: Estrogen receptor alpha
phosphorylated at tyrosine 537 is associated with poor clinical outcome
in breast cancer patients treated with tamoxifen. Horm Cancer 2010,
1:215–221.
8. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L,
Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L: Prognostic and
therapeutic implications of distinct kinase expression patterns in
different subtypes of breast cancer. Cancer Res 2010, 70:8852–8862.
9. Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet
M, Jacquemier J, Viens P, Birnbaum D, Bertucci F: Sixteen-kinase gene
expression identifies luminal breast cancers with poor prognosis. Cancer
Res 2008, 68:767–776.
10. Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa
BA, Photiou A, Tralau-Stewart C, Castellano L, Green AR, Coombes RC, Ellis
IO, Ali S, Lenz HJ, Stebbing J: Kinome screening for regulators of the
estrogen receptor identifies LMTK3 as a new therapeutic target in breast
cancer. Nat Med 2011, 17:715–719.
11. O’Regan R, Hawk NN: mTOR inhibition in breast cancer: unraveling the
complex mechanisms of mTOR signal transduction and its clinical
implications in therapy. Expert Opin Ther Targets 2011, 15:859–872.
12. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA:
Akt-induced endocrine therapy resistance is reversed by inhibition of
mTOR signaling. Ann Oncol 2007, 18:1323–1328.
13. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O’Reilly T, Evans DB, Chen S,
Lane HA: Dual inhibition of mTOR and estrogen receptor signaling
in vitro induces cell death in models of breast cancer. Clin Cancer Res
2005, 11:5319–5328.
14. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK: S6 kinase 1
regulates estrogen receptor alpha in control of breast cancer cell
proliferation. J Biol Chem 2009, 284:6361–6369.
15. Snell L, Watson P: Breast tissue banking: collection, handling, storage,
and release of tissue for breast cancer research. Methods Mol Med 2006,
120:3–24.
16. Watson P, Snell L, Parisien M: The NCIC-Manitoba Breast Tumor Bank: a
resource for applied cancer research. CMAJ 1996, 155:281–283.
17. CTRNet. [www.CTRNet.ca]
18. Skliris G, Leygue E, Curtis-Snell L, Watson P, Murphy L: Expression of
oestrogen receptor-beta in oestrogen receptor-alpha negative human
breast tumours. Br J Cancer 2006, 95:616–626.19. Weitsman G, Li L, Skliris G, Davie J, Ung K, Curtis-Snell L, Tomes L, Watson P,
Murphy L: Estrogen receptor-alpha phosphorylated at Serine 118 is
present at the promoters of estrogen-regulated genes and is not altered
due to Her2 over-expression. Cancer Res 2006, 66:10162–10170.
20. Walsh S, Flanagan L, Quinn C, Evoy D, McDermott EW, Pierce A, Duffy MJ:
mTOR in breast cancer: differential expression in triple-negative and
non-triple-negative tumors. Breast 2012, 21:178–182.
21. Copp J, Manning G, Hunter T: TORC-specific phosphorylation of
mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker
for intact mTOR signaling complex 2. Cancer Res 2009, 69:1821–1827.
22. Rosner M, Schipany K, Hengstschläger M: p70 S6K1 nuclear localization
depends on its mTOR-mediated phosphorylation at T389, but not on its
kinase activity towards S6. Amino Acids 2012, 42:2251–2256.
23. Yin XJ, Wang G, Khan-Dawood FS: Requirements of phosphatidylinositol-3
kinase and mammalian target of rapamycin for estrogen-induced
proliferation in uterine leiomyoma- and myometrium-derived cell lines.
Am J Obstet Gynecol 2007, 196:176.
24. Kazi AA, Molitoris KH, Koos RD: Estrogen rapidly activates the PI3K/AKT
pathway and hypoxia-inducible factor 1 and induces vascular endothelial
growth factor A expression in luminal epithelial cells of the rat uterus. Biol
Reprod 2009, 81:378–387.
25. Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M,
Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A,
Harris AL, Berruti A: Down-regulation of phosphatidylinositol 3′-kinase/
AKT/molecular target of rapamycin metabolic pathway by primary
letrozole-based therapy in human breast cancer. Clin Cancer Res 2008,
14:2673–2680.
26. Yu J, Thomson TC, Johnson J: Cross talk between estradiol and mTOR
kinase in the regulation of ovarian granulosa proliferation. Reprod Sci
2012, 19:143–151.
27. Yu J, Henske EP: Estrogen-induced activation of mammalian target of
rapamycin is mediated via tuberin and the small GTPase Ras homologue
enriched in brain. Cancer Res 2006, 66:9461–9466.
28. Shrivastav A, Murphy L: Interactions of PI3K/Akt/mTOR and estrogen
receptor signaling in breast cancer. Breast Cancer Manage 2012, 1:235–249.
29. Bakarakos P, Theohari I, Nomikos A, Mylona E, Papadimitriou C, Dimopoulos
AM, Nakopoulou L: Immunohistochemical study of PTEN and
phosphorylated mTOR proteins in familial and sporadic invasive breast
carcinomas. Histopathology 2010, 56:876–882.
30. Bose S, Chandran S, Mirocha JM, Bose N: The Akt pathway in human
breast cancer: a tissue-array-based analysis. Mod Pathol 2006, 19:238–245.
31. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith
TL, Shi D, Yu D: Activation of the Akt/mammalian target of rapamycin/
4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in
breast cancers. Clin Cancer Res 2004, 10:6779–6788.
32. Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T,
Nordenskjold B, Stal O: Activation of Akt, mTOR, and the estrogen
receptor as a signature to predict tamoxifen treatment benefit. Breast
Cancer Res Treat 2013, 137:397–406.
33. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J,
Tujague M, Strom A, Treuter E, Warner M, Gustafsson JA: Estrogen
receptors: how do they signal and what are their targets. Physiol Rev
2007, 87:905–931.
34. Osborne C, Schiff R: Estrogen-receptor biology: continuing progress and
therapeutic implications. J Clin Oncol 2005, 23:1616–1622.
35. Schiff R, Massarweh S, Shou J, Bharwani L, Mohsin S, Osborne C: Cross-talk
between estrogen receptor and growth factor pathways as a molecular
target for overcoming endocrine resistance. Clin Cancer Res 2004,
10:331S–336S.
36. Phosphonet. [http://www.phosphonet.ca]
37. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev
2004, 18:1926–1945.
38. Lippman M, Bolan G: Oestrogen responsive human breast cancer in long
term tissue culture. Nature 1975, 256:592–593.
39. Lippman M, Bolan G, Huff K: Effects of estrogens and antiestrogens on
hormone-responisve human breast cancer in long-term tissue culture.
Cancer Res 1976, 36:4595–4601.
40. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ,
Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C,
Carroll JS: Differential oestrogen receptor binding is associated with
clinical outcome in breast cancer. Nature 2012, 481:389–393.
Shrivastav et al. Breast Cancer Research 2014, 16:R49 Page 13 of 13
http://breast-cancer-research.com/content/16/3/R4941. Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A’Hern R, Nerurkar A, Osin P,
Smith IE, Dowsett M: Extreme loss of immunoreactive p-Akt and p-Erk1/2
during routine fixation of primary breast cancer. Breast Cancer Res 2010,
12:R76.
42. Neumeister VM, Anagnostou V, Siddiqui S, England AM, Zarrella ER,
Vassilakopoulou M, Parisi F, Kluger Y, Hicks DG, Rimm DL: Quantitative
assessment of effect of preanalytic cold ischemic time on protein
expression in breast cancer tissues. J Natl Cancer Inst 2012, 104:1815–1824.
43. Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S,
Deng J, VanMeter AJ, Geho DH, Pastore L, Sennesh J, Petricoin EF 3rd, Liotta
LA: A portrait of tissue phosphoprotein stability in the clinical tissue
procurement process. Mol Cell Proteomics 2008, 7:1998–2018.
44. Hiller T, Snell L, Watson P: Microdissection/RT-PCR analysis of gene
expression. Biotechniques 1996, 21:38–44.
45. Barnes RO, Parisien M, Murphy LC, Watson PH: Influence of evolution in
tumor biobanking on the interpretation of translational research. Cancer
Epidemiol Biomarkers Prev 2008, 17:3344–3350.
doi:10.1186/bcr3660
Cite this article as: Shrivastav et al.: The mechanistic target for
rapamycin pathway is related to the phosphorylation score for estrogen
receptor-α in human breast tumors in vivo. Breast Cancer Research
2014 16:R49.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
